Boehringer Ingelheim
For Healthcare Professionals
All products

All Products

Metabolic

Jardiance

About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.

1Diabetes Atlas 8th edition 2017, International Diabetes Federation.http://www.diabetesatlas.org (link is external) (accessed Apr 2018)

Learn More
Empagliflozin (Jardiance)

Empagliflozin (Jardiance®)

Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control and to reduce the risk of cardiovascular death in patients with established cardiovascular disease.
Learn More
Learn More
Linagliptin (Trajenta)

Linagliptin (Trajenta®)

Linagliptin (Trajenta®) is indicated in adults patients with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise, as monotherapy or as add-on to metformin, a sulphonylurea, insulin (with or without metformin) or metformin plus a sulphonylurea.
Learn More

Cardiovascular

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).

1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.

Learn More
Dabigatran etexilate (Pradaxa)

Dabigatran etexilate (Pradaxa®)

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Learn More
Learn More
Micardis

Telmisartan (Micardis®)

Telmisartan (Micardis®) is an angiotensin receptor blocker (ARB) that is used in the treatment of essential hypertension. Micardis® 80mg once a day is also indicated for reduction of the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years of age or older at high risk of developing major cardiovascular events. High risk of cardiovascular events can be evidenced by history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage.
Learn More

Oncology

Cancer takes. Takes away loved ones, time and invaluable milestones. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.

Learn More
Afatinib (Giotrif)

Afatinib (Giotrif®)

For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum based chemotherapy.11. GIOTRIF® Summary of Product Characteristics 2018
Learn More

Respiratory

Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.